Voltaren and Emulgel makers fined $4.5m for misleading consumers over pain relief gels

Novartis and GlaxoSmithKline marketed and priced the products differently when in fact they were identical, federal court finds

The federal court has ordered a pharmaceutical company that produces the pain relief gels Voltaren Osteo Gel and Emulgel to pay $4.5m in penalties for marketing and pricing the products differently when in fact they were identical.

Emulgel is marketed for the temporary relief of local pain and inflammation. Osteo Gel was, between 2012 and 2017, marketed for the relief of osteoarthritis symptoms.

Continue reading...
https://ift.tt/eA8V8J
from World news | The Guardian